Sawicki Mark W 4
4 · Cryoport, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
Cryoport, Inc.CYRX
Sawicki Mark W
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-03-10$4.88/sh−1,583$7,724→ 78,528 total - Exercise/Conversion
Common Stock
2025-03-09+2,667→ 80,111 total - Exercise/Conversion
Restricted Stock Rights
2025-03-09−2,667→ 0 total→ Common Stock (2,667 underlying)
Footnotes (3)
- [F1]Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock.
- [F2]Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
- [F3]The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2025.